Company: LIMN
Filing Date: 2025-01-16
Form Type: POS AM
Source: 0001104659-25-003835
Chunk: 252

Company: Liminatus Pharma, Inc.
Filing Date: 2025-01-16
Form: POS AM
Chunk 252
---
 that on July 24, 2024, Hana Immunotherapeutics, LLC, an affiliate of Chris Kim, the Chief Executive Officer of Liminatus, agreed to loan the buyer of the former managing member of the Company’s Sponsor approximately $1.216 million, to facilitate the Acquisition. As a result of the Acquisition, the former managing

<div align='center'>119</div>

TABLE OF CONTENTS

member, Columbass Limited, resigned as managing member of the Sponsor on October 30, 2024, and Iris Equity Holdings LLC was appointed as managing member of the Sponsor. Other than repayment of the principal and interest on the loan, which has been settled through the delivery of shares in a private Korean company, Mr. Kim has stated that he has no affiliation or other relationship with the Sponsor, any of the Sponsor’s members, including the former and new managing member or the buyer of the former managing member of our Sponsor; and • the fact that Sponsor and its affiliates may receive a positive rate of return on their investments in Iris, even if other stockholders of Iris do not receive a positive rate of return on their investments. Redemption Rights Pursuant to our charter and the Trust Agreement, eligible holders of the Iris Class A Shares may elect to have their shares redeemed for cash at a redemption price per share calculated in accordance with our charter, by tendering the Iris Class A Shares of such holder for redemption not later than 5:00 p.m. Eastern Time on the date that is two Business Days prior to the date of the Special Meeting. As of January 2, 2025, this would have amounted to approximately $11.47 per share (net of all applicable taxes payable from the Trust Account). If a holder of public shares properly exercises his, her or its redemption rights, then such holder will be exchanging his, her or its shares of Iris Class A Common Stock for cash and will no longer own such shares. See the section entitled “ Special Meeting of Iris Stockholders — Redemption Rights and Procedures ” for procedures to be followed if you wish to redeem your shares for cash and not own the ParentCo common stock following consummation of the Business Combination. After the special stockholders meeting held by Iris on December 20, 2024, to vote upon a charter amendment to extend the time to complete a business combination until March 31, 2025 (subject to an additional three month extension at the discretion of the Board), public stockholders elected to redeem 64,453 shares of common